Navigation Links
GFX: Wrinkle-Killer or Botox(R) Hit-Man?
Date:3/10/2008

NORTH DALLAS, Texas and PLANO, Texas, March 10 /PRNewswire/ -- Tired of frequent Botox injection visits? GFX might be the long-term wrinkle solution for you!

Newly-FDA approved GFX (Glabella Furrow Relaxation) recently arrived in North Texas and is already making waves -- radiofrequency waves, to be exact -- in select aesthetic centers and cosmetic surgery offices. GFX is a unique technological advancement in facial rejuvenation that offers long-term relaxation of overactive 'frown' muscles; a proposition likely to thrill many long-time Botox users, but one that targets the Botox(R) empire for a kill-shot where it would hurt the most ... right between the eyebrows.

Botox(R) muscle-relaxing injection results typically last from 3 to 4 months on average, while the results of one in-office GFX (sometimes called 'No-tox') treatment averages 18 months or longer. According to Jeffrey Adelglass, M.D., F.A.C.S., a popular North Dallas area cosmetic surgeon who has had plenty of experience working with a variety of cosmetic injectables, treatment of the glabella area alone constitutes approximately 65% -- the lion's share -- of his Botox injections. While his GFX patients might still receive periodic Botox(R) injections in other forehead areas (GFX is currently only FDA-approved for the glabella), sometimes keeping the glabella relaxed can, over time, soften wrinkles in other forehead areas, as well. An observed effect of the treatment has been that eyebrows gradually tend to become more elevated and horizontal forehead lines reduced, potentially eliminating the need for elective surgery or neurotoxin injections entirely for some aesthetic patients.

How does GFX work? This minimally-invasive, in-office procedure utilizes a specified dose of radiofrequency (RF) thermal energy, delivered through an insulated bipolar needle inserted near the eyebrows, on either side of the forehead. First, the doctor delivers a stimulating pulse through the needle tome and recovery.

Contact:

Pamela Fox, Director of Communications, 972-620-3223


'/>"/>
SOURCE SKINTASTIC Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
2. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... , ... Cellairis is a worldwide mobile device and computer repair franchise that ... and Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up ... accessibility for customers. While customers do their shopping, Cellairis can accomplish a number of ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a ... , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is ... in a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic Supplies ... ... the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides separate ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a six-year ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: